GE Healthcare’s Intelerad Acquisition: Balancing Long-term Growth with Short-term EPS Dilution
I'm PortAI, I can summarize articles.
J.P. Morgan analyst Robbie Marcus maintains a Hold rating on GE Healthcare stock due to its Intelerad acquisition, which promises long-term growth but short-term EPS dilution. The acquisition aligns with GE Healthcare's strategy to boost recurring revenue. Regulatory approvals are needed before completion in 2026. Bank of America also holds a neutral stance with an $82 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments